BBOT Q3 10-Q: Loss Narrows to $34.2M, Cash $315.3M, Prior EPS Restated
BBOT is trading near its 52-week low of $1.98 (10% above the low).
Summary
Q3 loss narrowed to $34.2M with $315.3M in cash funding operations into 2029, matching the morning 8-K. The 10-Q adds a restatement of prior per-share losses from a share-count error and discloses a sub-$5M payment claim from UCSF that the company disputes.
Key Events · Earnings and Guidance · BBOT
-
Q3 Loss Narrows to $34.2M
Net loss was $34.2M for Q3 2026 versus $44.8M in Q3 2025, with R&D down to $29.6M from $35.1M and G&A down to $7.9M from $14.1M.
-
Cash of $315.3M Funds Into 2029
Cash, cash equivalents and marketable securities totaled $315.3M at September 30, 2026; the ATM program had sold no shares as of that date.
-
Prior Per-Share Losses Restated
Previously reported net loss per share of $(526.11), $(705.20) and $(1,230.89) for Q1 2026, Q2 2026 and the six months are corrected to $(0.53), $(0.70) and $(1.23) after a share-count-in-thousands error; deemed immaterial.
-
UCSF Claims Sub-$5M Payment
UCSF asserts an Indexed Milestone Payment of less than $5.0 million is or will become due following the de-SPAC closing; the company disagrees and believes nothing is owed.
Analysis · BBOT · Life Sciences
The headline numbers match the 8-K filed minutes earlier: Q3 net loss of $34.2M versus $44.8M a year ago, and $315.3M of cash and securities that management says funds operations into 2029. What is new in the 10-Q is a correction of previously reported per-share losses for the first half of 2026 — the company had used share counts in thousands, producing absurd figures like $(526.11) per share that are now restated to $(0.53) and $(0.70). Labeled immaterial, the fix does not touch the balance sheet, but it is a reporting-quality blemish on a company that previously disclosed a material weakness in internal controls. The filing also reveals a dispute with UCSF, which claims an Indexed Milestone Payment of under $5.0 million is owed after the de-SPAC; the company says nothing is due. Neither item changes the cash runway, but both are worth knowing before the Q4 monotherapy data updates for BBO-11818 and BBO-10203.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBOT was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $176.4M. The 52-week trading range was $1.98 to $14.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.